Iron sucrose augments homocysteine-induced endothelial dysfunction in normal subjects
Open accessThe DOI matches its Crossref record; 62 of the 64 references it cites were found in a registry or an index.
Abstract
Intravenous iron is commonly used in conjunction with erythropoietic agents to treat anemia in patients with chronic kidney disease. Iron has been proposed to promote oxidative stress and endothelial dysfunction in vascular tissues. We studied the acute effects of intravenous iron sucrose on homocysteine-induced endothelial dysfunction in the brachial artery of normal human subjects. In all, 40 healthy subjects received intravenous iron sucrose 100 mg or placebo over 30 min immediately before ingestion of 100 mg/kg of oral methionine in a double-blind, randomized study. Flow- and nitroglycerin-mediated dilation in the brachial artery, serum markers of iron stores, and homocysteine and nitrotyrosine levels were measured before and after study drug administration. Intravenous iron significantly increased transferrin saturation and non-transferrin-bound iron (NTBI) when compared with placebo. Flow-mediated dilation significantly decreased from baseline 1 h after administration of iron sucrose when compared with placebo (from 6.66+/-0.47 to 1.93+/-0.35% after iron sucrose vs from 6.00+/-0.40 to 5.61+/-0.46% after placebo, P<0.001), but did not differ between groups at 4 h (1.10+/-0.39 vs 1.33+/-0.51%). Nitroglycerin-mediated vasodilation, and homocysteine and 3-nitrotyrosine levels did not differ after administration of iron sucrose and placebo. Intravenous administration of iron sucrose in the setting of transient hyperhomocysteinemia induced by methionine ingestion significantly increased transferrin saturation and plasma levels of NTBI and significantly attenuated flow-mediated dilation in the brachial artery when compared with placebo. This potential mechanistic link between intravenous iron and endothelial dysfunction warrants further study of cardiovascular effects of intravenous iron in anemic chronic kidney disease populations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the well-known adverse vascular effects of homocysteine (in inhibiting flow-mediated dilatation) are in fact iron-dependent [701-703]”
Citations
Cites
Corretti, M. C., Anderson, T. J., Benjamin, E. J., Celermajer, D., Charbonneau, F., Creager, M. A., Deanfield, J., Drexler, H., Gerhard-Herman, M., Herrington, D., et al. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01746-6 · Cited by 4,604
Besarab, A., Bolton, W. K., Browne, J. K., Egrie, J. C., Nissenson, A. R., Okamoto, D. M., Schwab, S. J., & Goodkin, D. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808273390903 · Cited by 1,930
Regulatory Functions of the Vascular Endothelium
Epstein, F. H., Vane, J. R., Änggård, E. E., & Botting, R. M. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007053230106 · Cited by 1,889
Nitric oxide, oxidants, and protein tyrosine nitration
Radi, R. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307446101 · Cited by 1,457
Kalantar-Zadeh, K. (2017) · American Journal of Nephrology · doi:10.1159/000455387 · Cited by 1,148
IRON AND THE SEX DIFFERENCE IN HEART DISEASE RISK
Sullivan, J. (1981) · The Lancet · doi:10.1016/s0140-6736(81)92463-6 · Cited by 969
The oxidant stress of hyperhomocyst(e)inemia.
Loscalzo, J. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118776 · Cited by 717
Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum
Ubbink, J. B., Hayward Vermaak, W. J., & Bissbort, S. (1991) · Journal of Chromatography B: Biomedical Sciences and Applications · doi:10.1016/0378-4347(91)80407-4 · Cited by 678
Homocyst(e)ine Decreases Bioavailable Nitric Oxide by a Mechanism Involving Glutathione Peroxidase
Upchurch, G. R., Welch, G. N., Fabian, A. J., Freedman, J. E., Johnson, J. L., Keaney, J. F., & Loscalzo, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.27.17012 · Cited by 668
Jones, M., Ibels, L., Schenkel, B., & Zagari, M. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00450.x · Cited by 665
Association of Nitrotyrosine Levels With Cardiovascular Disease and Modulation by Statin Therapy
Shishehbor, M. H., Aviles, R. J., Brennan, M.-L., Fu, X., Goormastic, M., Pearce, G. L., Gokce, N., Keaney, J. F., Penn, M. S., Sprecher, D. L., et al. (2003) · JAMA · doi:10.1001/jama.289.13.1675 · Cited by 464
Interactions of oxidants with vascular signaling systems
Wolin, M. S. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.6.1430 · Cited by 463
Chambers, J. C., McGregor, A., Jean-Marie, J., Obeid, O. A., & Kooner, J. S. (1999) · Circulation · doi:10.1161/01.cir.99.9.1156 · Cited by 428
Kanani, P. M., Sinkey, C. A., Browning, R. L., Allaman, M., Knapp, H. R., & Haynes, W. G. (1999) · Circulation · doi:10.1161/01.cir.100.11.1161 · Cited by 418
How the Target Hemoglobin of Renal Anemia Should Be?
Mimura, I., Tanaka, T., & Nangaku, M. (2015) · Nephron · doi:10.1159/000440849 · Cited by 416
Iron regulates nitric oxide synthase activity by controlling nuclear transcription.
Weiss, G., Werner-Felmayer, G., Werner, E. R., Grünewald, K., Wachter, H., & Hentze, M. W. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.3.969 · Cited by 412
Duan, W., Ladenheim, B., Cutler, R. G., Kruman, I. I., Cadet, J. L., & Mattson, M. P. (2002) · Journal of Neurochemistry · doi:10.1046/j.0022-3042.2001.00676.x · Cited by 405
IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000
(2001) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(01)70008-x · Cited by 400
Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia
Eberhardt, R. T., Forgione, M. A., Cap, A., Leopold, J. A., Rudd, M. A., Trolliet, M., Heydrick, S., Stark, R., Klings, E. S., Moldovan, N. I., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8342 · Cited by 391
Bellamy, M. F., McDowell, I. F. W., Ramsey, M. W., Brownlee, M., Bones, C., Newcombe, R. G., & Lewis, M. J. (1998) · Circulation · doi:10.1161/01.cir.98.18.1848 · Cited by 336
Katz, S. D., Balidemaj, K., Homma, S., Wu, H., Wang, J., & Maybaum, S. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00790-7 · Cited by 300
Self-citationPonka, P. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.055suppl.69002.x · Cited by 274
Nappo, F. (1999) · JAMA · doi:10.1001/jama.281.22.2113 · Cited by 270
Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease
Agarwal, R., Vasavada, N., Sachs, N. G., & Chase, S. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00648.x · Cited by 261
Impaired Homocysteine Metabolism and Atherothrombotic Disease
Durand, P., Prost, M., Loreau, N., Lussier-Cacan, S., & Blache, D. (2001) · Laboratory Investigation · doi:10.1038/labinvest.3780275 · Cited by 261
Roest, M., van der Schouw, Y. T., de Valk, B., Marx, J. J. M., Tempelman, M. J., de Groot, P. G., Sixma, J. J., & Banga, J. D. (1999) · Circulation · doi:10.1161/01.cir.100.12.1268 · Cited by 245
Cardiovascular Mortality in End-Stage Renal Disease
Collins, A. J. (2003) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200304000-00002 · Cited by 238
Tuomainen, T.-P., Kontula, K., Nyyssönen, K., Lakka, T. A., Heliö, T., & Salonen, J. T. (1999) · Circulation · doi:10.1161/01.cir.100.12.1274 · Cited by 232
Hazen, S. L., Zhang, R., Shen, Z., Wu, W., Podrez, E. A., MacPherson, J. C., Schmitt, D., Mitra, S. N., Mukhopadhyay, C., Chen, Y., et al. (1999) · Circulation Research · doi:10.1161/01.res.85.10.950 · Cited by 228
Abnormalities of endothelial function in patients with predialysis renal failure
Thambyrajah, J., Landray, M. J., McGlynn, F. J., Jones, H. J., Wheeler, D. C., & Townend, J. N. (2000) · Heart · doi:10.1136/heart.83.2.205 · Cited by 225
Vaziri, N. D., Ni, Z., Oveisi, F., Liang, K., & Pandian, R. (2002) · Hypertension · doi:10.1161/hy0102.100540 · Cited by 224
Furuland, H. (2003) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/18.2.353 · Cited by 224
Parenteral iron formulations: A comparative toxicologic analysis and mechanisms of cell injury
Zager, R. A., Johnson, A. C. M., Hanson, S. Y., & Wasse, H. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.33917 · Cited by 209
Intravenous iron sucrose: Establishing a safe dose
Chandler, G., Harchowal, J., & Macdougall, I. C. (2001) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2001.28587 · Cited by 198 · cited 1×
“Baseline levels of ferritin and homocysteine were lower in women when o compared with men (ferritin 32 (50) vs 126 (93) ng/ml, P<0.”
BackgroundVitamin E Attenuates Oxidative Stress Induced by Intravenous Iron in Patients on Hemodialysis
ROOB, J. M., KHOSCHSORUR, G., TIRAN, A., HORINA, J. H., HOLZER, H., & WINKLHOFER-ROOB, B. M. (2000) · Journal of the American Society of Nephrology · doi:10.1681/asn.v113539 · Cited by 193
Administration of Parenteral Iron and Mortality among Hemodialysis Patients
Feldman, H. I., Joffe, M., Robinson, B., Knauss, J., Cizman, B., Guo, W., Franklin-Becker, E., & Faich, G. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000128009.69594.be · Cited by 192
Quantification of Non-Transferrin-Bound Iron in the Presence of Unsaturated Transferrin
Gosriwatana, I., Loreal, O., Lu, S., Brissot, P., Porter, J., & Hider, R. C. (1999) · Analytical Biochemistry · doi:10.1006/abio.1999.4216 · Cited by 168
Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy
Lim, P.-S., Wei, Y.-H., Yu, Y. L., & Kho, B. (1999) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/14.11.2680 · Cited by 167
Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo
Rooyakkers, T. M., Stroes, E. S. G., Kooistra, M. P., Van Faassen, E. E., Hider, R. C., Rabelink, T. J., & Marx, J. J. M. (2002) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2002.0320s1009.x · Cited by 157
Chao, C.-L., Kuo, T.-L., & Lee, Y.-T. (2000) · Circulation · doi:10.1161/01.cir.101.5.485 · Cited by 146
Parkkinen, J., von Bonsdorff, L., Peltonen, S., Grönhagen‐Riska, C., & Rosenlöf, K. (2000) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/15.11.1827 · Cited by 136
Endothelium-dependent vasodilatation is impaired in peritoneal dialysis patients
van Guldener, C. (1998) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/13.7.1782 · Cited by 125
Oxidative stress and chronic renal failure: markers and management.
Massy, Z. A., & Nguyen‐Khoa, T. (2002) · PubMed · Cited by 115
Espósito, B. P., Breuer, W., Slotki, I., & Cabantchik, Z. I. (2002) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2002.0320s1042.x · Cited by 115
Iron overload and cardiovascular complications in dialysis patients
Kletzmayr, J., & Hörl, W. H. (2002) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/17.suppl_2.25 · Cited by 113
Labile iron in parenteral iron formulations: a quantitative and comparative study
Wyck, D. V., Anderson, J., & Johnson, K. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg579 · Cited by 99
Chambers, J. C., Ueland, P. M., Wright, M., Doré, C. J., Refsum, H., & Kooner, J. S. (2001) · Circulation Research · doi:10.1161/hh1401.093459 · Cited by 97
An Indistinct Balance: The Safety and Efficacy of Parenteral Iron Therapy
BESARAB, A., FRINAK, S., & YEE, J. (1999) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1092029 · Cited by 91
Beshara, S., Lundqvist, H., Sundin, J., Lubberink, M., Tolmachev, V., Valind, S., Antoni, G., Långström, B., & Danielson, B. G. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01179.x · Cited by 86
Kooistra, M. P., Kersting, S., Gosriwatana, I., Lu, S., Nijhoff‐Schutte, J., Hider, R. C., & Marx, J. J. M. (2002) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2002.0320s1036.x · Cited by 84
Lim, C. S., & Vaziri, N. D. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00580.x · Cited by 84
Iron sucrose: The oldest iron therapy becomes new
Yee, J., & Besarab, A. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.36853 · Cited by 83
Sullivan, J. L. (2004) · Journal of Laboratory and Clinical Medicine · doi:10.1016/j.lab.2004.10.006 · Cited by 82
Colombo, P. C., Ashton, A. W., Celaj, S., Talreja, A., Banchs, J. E., Dubois, N. B., Marinaccio, M., Malla, S., Lachmann, J., Ware, J. A., et al. (2002) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00680.2001 · Cited by 79
Induction of Ferritin Synthesis in Human Lung Epithelial Cells Treated with Crocidolite Asbestos
Fang, R., & Aust, A. E. (1997) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1997.9892 · Cited by 52
Ali, A., Zhang, Q., Dai, J., & Huang, X. (2003) · BioMetals · doi:10.1023/a:1020642808437 · Cited by 49
Self-citationThe iron hypothesis:does iron play a role in atherosclerosis?
Meyers, D. G. (2000) · Transfusion · doi:10.1046/j.1537-2995.2000.40081023.x · Cited by 45
Mancini, G. B. J. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.11.017 · Cited by 44
Beshara, S., Lundqvist, H., Sundin, J., Lubberink, M., Максимилианович, Т. В., Valind, S., Antoni, G., Långström, B., & Danielson, B. G. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01170.x · Cited by 35
Reliability of serum iron, ferritin, nitrite, and association with risk of renal cancer in women
Ali, M., Akhmedkhanov, A., Zeleniuch‐Jacquotte, A., Toniolo, P. G., Frenkel, K., & Huang, X. (2003) · Cancer Detection and Prevention · doi:10.1016/s0361-090x(03)00027-8 · Cited by 33
Self-citationEffect of Dexrazoxane on Homocysteine-Induced Endothelial Dysfunction in Normal Subjects
Zheng, H., Dimayuga, C., Hudaihed, A., & Katz, S. D. (2002) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000023187.25914.5b · Cited by 33
Self-citationÇavdar, C., Artmann, A. T., Yeniçerioğlu, Y., Uysal, S., Çelik, A., Sifil, A., Önvural, B., & Çamsarı, T. (2003) · Scandinavian Journal of Urology and Nephrology · doi:10.1080/00365590310008758 · Cited by 33
Cited by
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
“) It is of particular interest that the well-known adverse vascular effects of homocysteine (in inhibiting flow-mediated dilatation) are in fact irondependent [608-610], and that reducing homocysteine (e.”
BackgroundThe Role of Iron in Diabetes and Its Complications
Swaminathan, S., Fonseca, V. A., Alam, M. G., & Shah, S. V. (2007) · Diabetes Care · doi:10.2337/dc06-2625 · Cited by 423
A randomized trial of intravenous and oral iron in chronic kidney disease
Agarwal, R., Kusek, J. W., & Pappas, M. K. (2015) · Kidney International · doi:10.1038/ki.2015.163 · Cited by 200
Acute Injury with Intravenous Iron and Concerns Regarding Long-Term Safety
Bishu, K., & Agarwal, R. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01420406 · Cited by 98
“(31) evaluated in a double-blind, controlled experiment the effect of iron sucrose given in a recommended dose (100 mg) but at a slower rate (30 min rather than 5 min) to assess its effect on endothelial function as measured by flow-mediated dilation in 40 healthy volunteers.”
BackgroundGhafourian, K., Shapiro, J. S., Goodman, L., & Ardehali, H. (2020) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2019.08.009 · Cited by 106
Metadata
- Authors
- Zheng, H., Huang, X., Zhang, Q., & Katz, S. D.
- Affiliations
- Yale University (US)
- New York University (US)
- Corresponding author
- Katz, S.D.
- Venue
- Kidney International
- Publisher
- Elsevier BV
- Published
- 2006-02
- Volume
- 69
- Issue
- 4
- Pages
- 679-684
- ISSN
- 0085-2538 (ISSN-L)
- PMC
- PMC2988421
- OpenAlex
- W2067573387
- Cited by
- 44
- References
- 64
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 2 · 2021: 3 · 2020: 3 · 2019: 2 · 2018: 1 · 2017: 1 · 2016: 2 · 2015: 3 · 2014: 2 · 2013: 2 · 2012: 3
- FWCI
- 1.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 3596 d)
- Locations
- Kidney International (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Amgen
- Yale University
- National Center for Research Resources ((5 MO1 RR00645, M01RR000645)
- NIH Clinical Center
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
- Keywords
- iron sucrose, endothelial dysfunction, homocysteine, hyperhomocysteinemia, flow-mediated dilation, non-transferrin-bound iron, transferrin saturation, nitrotyrosine, oxidative stress, brachial artery, intravenous iron, anemia of chronic kidney disease, cardiovascular risk
- MeSH terms
- Ferric Oxide, Saccharated, Adult, Brachial Artery, Cardiovascular Diseases, Chelating Agents, Double-Blind Method, Endothelium, Vascular, Female, Ferric Compounds, Ferritins, Glucaric Acid, Nitroglycerin, Homocysteine, Humans, Iron, Male, Methionine, Razoxane, Regional Blood Flow, Risk Factors, Transferrin, Tyrosine, Vasodilation, Oxidative Stress, Anemia, Iron-Deficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.